Table 1.
A: Baseline characteristics in patients with prolactinoma and controls; B: Metabolic and endocrine parameters in patients with prolactinoma at follow-up
| A | Controls | IQR or SD |
Prolactinomas | IQR or SD |
p-value controls vs. prolactinomas |
B | IQR or SD |
p-value baseline vs. follow-up |
|---|---|---|---|---|---|---|---|---|
| Prolactinomas follow-up | ||||||||
| Median or mean |
Median or mean |
Median or mean |
||||||
| Sex | 18 female (3 post-, 15 premenopausal), 12 male | 7 female (all premenopausal), 14 male | ||||||
| Age (years) | 36.7 | 11.0 | 40.0 | 17 | 0.418 | |||
| BMI (kg/m2) | 22.9 | 21.0–26.6 | 27.5 | 22.4–33.5 | 0.018 | 27.5 | 21.5–35.0 | 0.686 |
| BMI (kg/m2) in categories in absolute numbers (percent) | ||||||||
| −18.4 (underweight) | 1 (3.3%) | 1 (4.8%) | 0 (0%) | |||||
| 18.5–24.9 (normal) | 20 (66.7%) | 6 (28.6%) | 2 (9.5%) | |||||
| 25–29.9 (overweight) | 7 (23.3%) | 7 (33.3%) | 2 (9.5%) | |||||
| 30–34.9 (obese class I) | 1 (3.3%) | 4 (19%) | 1 (4.8%) | |||||
| 35–39.9 (class II) | 0 (0%) | 3 (14.3%) | 1 (4.8% | |||||
| ≥ 40 (class III) | 1 (3.3%) | 0 (0%) |
0 (0%) 15 (71.4%) missing |
|||||
| WHR | 0.86 | 0.06 | 0.89 | 0.12 | 0.309 | |||
| Systolic BP (mmHg) | 129 | 17 | 129 | 21 | 0.997 | |||
| Diastolic BP (mmHG) | 85 | 13 | 84 | 15 | 0.921 | |||
| Prolactin (ng/ml) | 9.3 | 7.5–12.4 | 247.7 | 105.0–722.6 | < 0.001 | 11.6 | 7.6–30.4 | < 0.001 |
| Total cholesterol (mg/dl) | 192.6 | 45.0 | 212.5 | 36.2 | 0.099 | 196.9 | 40.6 | 0.018 |
| LDL (mg/dl) | 94.5 | 80–127.5 | 130 | 107–147.5 | < 0.001 | 106.5 | 94.3–148 | 0.018 |
| HDL (mg/dl) | 69.2 | 14.6 | 56.0 | 16.7 | 0.004 | 55.7 | 21.2 | 0.543 |
| Triglycerides (mg/dl) | 66.5 | 53.8–101.0 | 84.0 | 62.0–159.0 | 0.075 | 84.5 | 60–168.3 | 0.142 |
| Fasting glucose (mg/dl) | 89 | 86–93 | 88 | 86–96 | 0.939 | 87 | 82–91.5 | 0.191 |
| HOMA-IR | 1.89 | 1.40–3.11 | 2.32 | 1.64–3.59 | 0.151 | |||
| HbA1c (mmol/mol) | 33 | 31.0–34.0 | 34 | 32.5–35.5 | 0.069 | |||
| Adiponectin (μg/ml) | 8.8 | 6.1–13.3 | 9.3 | 7.0–11.5 | 0.723 | |||
| Homocystein (μmol/l) | 9.6 | 8.0–11.2 | 8.8 | 8.0–12.3 | 0.926 | |||
| CRP (mg/l) | 0.8 | 0.6–2.0 | 1.3 | 0.6–3.9 | 0.427 | |||
| Estradiol (premenopausal women only) (pg/ml) | 162.5 | 69.4 | 63.0 | 47.0 | 0.030 | 61.8 | 39.2 | 0.318 |
| Total testosterone (men only) (ng/ml) | 3.8 | 1.5 | 1.3 | 0.6 | < 0.001 | 2.4 | 1.0 | < 0.001 |
|
Free testosterone (men only) (ng/dl) |
16.6 | 4.6 | 5.6 | 2.7 | < 0.001 | 9.6 | 4.2 | 0.006 |
| LH (mIE/ml) | 6.3 | 3.9–10.3 | 3.6 | 1.7–5.1 | 0.001 | 4.0 | 2.6–5.2 | 0.171 |
| FSH (mIE/ml) | 5.8 | 3.9–7.9 | 3.4 | 2.5–6.1 | 0.003 | 4.7 | 3.3–5.5 | 0.020 |
| TSH (μU/ml) | 2.1 | 0.8 | 1.9 | 0.7 | 0.421 | 2.3 | 1.2 | 0.333 |
| fT4 (pmol/L) | 15.0 | 13.3–16-0 | 13.4 | 12.5–14.7 | 0.051 | 14.9 | 12.4–15.9 | 0.127 |
| fT3 (pmol/L) | 4.9 | 0.7 | 4.1 | 0.7 | < 0.001 | 4.7 | 0.6 | < 0.001 |
| % fat arms | 30.5 | 9.9 | 31.7 | 7.7 | 0.619 | |||
| % fat legs | 30.4 | 9.4 | 31.3 | 6.9 | 0.716 | |||
| % fat trunk | 31.7 | 10.2 | 36.8 | 11.1 | 0.099 | |||
| % fat android | 32.1 | 12.4 | 38.5 | 13.7 | 0.089 | |||
| % fat gynoid | 33.6 | 9.7 | 35.5 | 7.6 | 0.463 | |||
| % fat total body | 30.7 | 8.6 | 33.3 | 8.0 | 0.282 |
Patient characteristics and laboratory parameters at baseline in patients and controls and at follow-up in patients. Data are presented as mean and standard deviation or median and interquartile range depending on distribution of data.
BMI body mass index, WHR waist-hip ratio, LDL low-density lipoprotein, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, HbA1c glycated haemoglobin, CRP C-reactive protein, LH luteinizing hormone, FSH follicle-stimulating hormone, TSH thyroid-stimulating hormone, fT4 free thyroxine, fT3 free triiodothyronine;